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An unrealized potential to understand the genetic basis of aging in humans, is to consider the immense survival
advantage of the rare individuals who live 100 years or more. The Longevity Gene Study was initiated in 1998 at the
Albert Einstein College of Medicine to investigate longevity genes in a selected population: the ‘‘oldest old’’ Ashkenazi
Jews, 95 years of age and older, and their children. The study proved the principle that some of these subjects are
endowed with longevity-promoting genotypes. Here we reason that some of the favorable genotypes act as
mechanisms that buffer the deleterious effect of age-related disease genes. As a result, the frequency of deleterious
genotypes may increase among individuals with extreme lifespan because their protective genotype allows disease-
related genes to accumulate. Thus, studies of genotypic frequencies among different age groups can elucidate the
genetic determinants and pathways responsible for longevity. Borrowing from evolutionary theory, we present
arguments regarding the differential survival via buffering mechanisms and their target age-related disease genes in
searching for aging and longevity genes. Using more than 1,200 subjects between the sixth and eleventh decades of
life (at least 140 subjects in each group), we corroborate our hypotheses experimentally. We study 66 common allelic
site polymorphism in 36 candidate genes on the basis of their phenotype. Among them we have identified a candidate-
buffering mechanism and its candidate age-related disease gene target. Previously, the beneficial effect of an
advantageous cholesteryl ester transfer protein (CETP-VV) genotype on lipoprotein particle size in association with
decreased metabolic and cardiovascular diseases, as well as with better cognitive function, have been demonstrated.
We report an additional advantageous effect of the CETP-VV (favorable) genotype in neutralizing the deleterious
effects of the lipoprotein(a) (LPA) gene. Finally, using literature-based interaction discovery methods, we use the set of
longevity genes, buffering genes, and their age-related target disease genes to construct the underlying subnetwork
of interacting genes that is expected to be responsible for longevity. Genome wide, high-throughput hypothesis-free
analyses are currently being utilized to elucidate unknown genetic pathways in many model organisms, linking
observed phenotypes to their underlying genetic mechanisms. The longevity phenotype and its genetic mechanisms,
such as our buffering hypothesis, are similar; thus, the experimental corroboration of our hypothesis provides a proof
of concept for the utility of high-throughput methods for elucidating such mechanisms. It also provides a framework
for developing strategies to prevent some age-related diseases by intervention at the appropriate level.
Citation: Bergman A, Atzmon G, Ye K, MacCarthy T, Barzilai N (2007) Buffering mechanisms in aging: A systems approach toward uncovering the genetic component of
aging. PLoS Comput Biol 3(8): e170. doi:10.1371/journal.pcbi.0030170
Introduction
While life-style factors such as obesity have been identiﬁed
as limiting factors in life expectancy [1], genetic factors have
been implicated in, and are considered central to, the process
of aging. These genetic factors are obvious simply from
observing the change in maximal life span between species,
and the effect of single genes on longevity in several
invertebrates [2–4]. However, the long list of biological
processes associated with aging has not permitted all the
causes of mammalian aging to be determined. Monogenetic
disorders such as abnormalities in the LDL receptor gene
[5,6], the rare helicase gene defects in Werner syndrome that
prevent subjects from attaining normal lifespan [7], and the
more common BRCA1 and BRCA2 genes in breast cancer [8],
all represent genetically determined phenotypic defects
associated with early mortality. However, these are not
necessarily common mechanisms of aging, and despite the
evidence for a substantial genetic component, the inherited
biological factors [9] that deﬁne lifespan in long-lived humans
remain unknown. In population-based studies, the incidence
and prevalence of age-related disease can be a marker of
aging. For example, in our Ashkenazi Jewish study, the
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APOC-3 (apolipoprotein C3) was found to be signiﬁcantly
higher among centenarians and their offspring than in the
control [10]. Signiﬁcantly lower serum levels for APOC-3 and
unique lipoprotein phenotype (lipoprotein particle size) were
noted among carriers of the  641C homozygote [10]. In
previous work, we examined the effect of the genotype on
aging by monitoring age–related disease as a clinically
relevant surrogate for aging. We showed that this favorable
APOC-3 genotype was associated with lower prevalence of
hypertension, CVD, and metabolic syndrome, in addition to
being signiﬁcantly more prevalent among centenarians and
their offspring than that of the control group. Furthermore, a
strong correlation was found with increase homozygosity for
the 405V variant in CETP (cholesteryl ester transfer protein)
[11] in centenarians, also associated with a unique lipoprotein
phenotype and lower prevalence of metabolic syndrome and
with preservation of cognitive function [12]. These observa-
tions further conﬁrm that aging is a complex trait, and
additionally, that genes associated with aging often have
pleiotropic effects. To address the complexity of aging, we
adopted an evolutionary approach in searching for genes
associated with longevity and the ‘‘aging phenotype,’’ which
includes age-related diseases, in humans. Evolutionary theory
can be summarized as the study of how genetic variation
within a population is translated into variation between
populations in response to natural selection, i.e., differential
reproduction over the course of many generations. Similar
principles can be applied to the study of changes in the
genetic makeup of populations in response to differential
survival over the course of one or two overlapping gener-
ations. Differential survival in response to mortality will
therefore be reﬂected in the prevalence of genotypes under-
lying the process of aging and longevity.
The studies reported here are based on the following three
assumptions: ﬁrst, exceptional longevity is a rare phenotype;
second, genotypes associated with age-related diseases are
‘‘weeded out,’’ while those genotypes associated with survival,
longevity genes, are enriched in an advanced age subpopu-
lation; third, some favorable longevity genotypes may act to
buffer the deleterious effects of other genes that lead to age-
related diseases. It is this third assumption that makes it
possible to discriminate between age-related disease geno-
types and the longevity genotype. Given cohorts representing
each decade of the lifespan, one can examine whether those
who continue to survive exhibit biologically distinctive
phenotypes and genotypes, when compared with those of
younger cohorts. Thus, the relative prevalence of favorable
longevity genotypes within the population can be expected to
rise monotonically rather than abruptly or intermittently
over the life course; conversely, the prevalence of age-related
diseases genotype is expected to monotonically decrease;
however, the prevalence of those deleterious genotypes that
are buffered may, paradoxically, be found to remain the same
(or increased) among individuals with extreme lifespan. Using
populations of Ashkenazi Jews consisting of individuals in the
age range 50–110 years (including ;400 individuals between
ages 95–110), indeed we observe a monotonic increase with
age for three genotypes: 1) the CETP gene codon 405
isoleucine to valine variant (CETP VV); 2) the APOC-3 gene
codon A ( 641) C variant (APOC-3 CC); 3) a deletion atþ2019
in the adiponectin (ADIPOQ) gene. The enrichment of the
CETP genotype is supported by evidence from two inde-
pendent populations [11,13]. Finally, we may explain why the
CETP-VV genotype appears to exhibit an additional advanta-
geous effect—the neutralization of the deleterious effects of
the LPA gene: from this follows the observed high prevalence
of the deleterious genotypic variant of LPA among the
centenarians.
Rationale for Genotyping Centenarians and Expected
Pattern with Aging
Aging is associated with a decline in the frequency of
survivors attaining older ages; i.e., the frequency of cente-
narians in human populations is only ;1/10,000 persons.
Given the evidence of a genetic basis for longevity [14–16], we
would expect the prevalence of favorable genotypes in genes
contributing to prolonged lifespan—i.e., longevity genes—to be
signiﬁcantly higher among centenarians relative to their
prevalence in a younger control population, as can be
observed for the favorable genotypes of CETP-VV and
APOC-3 in Figure 1 (see the discussion below). Furthermore,
although at birth the probability of living more than 100
years is ;1/10,000, this probability increases to ;1/250 when
an individual reaches his or her life expectancy (;80 years
old). We would therefore expect the frequencies of longevity
genotype to increase monotonically in progressively older age
groups. Figure 2 shows the expected monotonic increase for
the same genotypes, CETP-VV and APOC-3 (see also Figure
S1). In contrast, deleterious genotypes associated with ‘‘aging
phenotype’’ (e.g., age-related disease genes) would be expected
to decrease monotonically as mortality selects out individuals
with these deleterious genotypes. These considerations
suggest that changes in genotypic frequencies affecting
lifespan in different age groups can be detected and used to
determine the relevant genes associated with the aging
process.
However, the two components, longevity and an aging
phenotype, cannot be disentangled, since an increase of a
favorable genotype in a longevity gene necessarily results in a
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Author Summary
Previous research showed that the frequency of deleterious
genotype of some age-related disease decreases its prevalence as
the population ages, as expected, since subjects with deleterious
genotype are weeded out due to mortality. There exists, however, a
set of age-related genes whose deleterious genotype indeed
decreases up to ages 80–85, but subsequently increases monotoni-
cally, until by age 100 its prevalence is similar to that at age ;60.
Why is a known harmful genotype so prevalent among centenar-
ians? Most likely because this genotype is protected by longevity
genes. We corroborated this hypothesis by studying gene–gene
interactions between age-related disease genotypes and longevity
genotypes. Our findings suggest that individuals with the favorable
longevity genotype can have just as many deleterious aging
genotypes as the rest of the population because their longevity
genotype protects them from the harmful effects of the other. We
identify genes contributing to extreme lifespan as well as their
counterpart, age-related disease genes. Our findings provide a proof
of concept for the utility of high-throughput methods, and for
elucidating mechanisms by which longevity genes buffer the effects
of disease genes. Our approach gives hope for developing new
medications that will protect against several age-related diseases.
Buffering Mechanisms in Agingdecrease of the frequency of its complementary genotypes.
Similarly, a decline in prevalence of a deleterious genotype at
an age-related disease gene necessarily implies an increase in
its non-deleterious alternatives. Thus, a simple analysis of
monotonic increase or decrease in genotypic prevalence
across age groups is not sufﬁcient to discriminate between
longevity genes and their counterpart age-related disease
genes.
Identification and the Interpretation of a U-Shape Pattern
of Genotype with Aging
In this study, we introduce a possible solution to overcome
this limitation. As a ﬁrst step, we must consider the protective
effect that longevity genes might confer and what effect this
might have on lifespan. It has been shown that offspring of
centenarians are healthier than their appropriate age-
matched controls, supporting the notion of inheritance from
centenarians to their offspring [10,12,16–20]. This observa-
tion lends support to the hypothesis that longevity genes
might buffer the deleterious effect of certain genetically
determined age-related diseases. Genes associated with the
latter set of diseases are here termed buffered disease genes.
Figure 3 shows the frequency trend of the deleterious
genotypes of two age-related diseases genes, KLOTHO and
LPA, and indeed, centenarians are endowed with signiﬁcantly
higher deleterious genotype than the elder control group (80
years old), and in the case of LPA, even than that of the
younger group. The presence of a molecular buffering
mechanism has already been discussed and observed in
model organisms. Studies of buffering mechanisms such as
the chaperone HSP90 have demonstrated that in the wild-
type, under normal conditions, the hidden accumulated,
mostly deleterious, genetic variation is buffered and not
expressed phenotypically; however, when HSP909s function-
ality is compromised, that same genetic variation is translated
into, mostly deleterious, phenotypic variation [21,22]. Further
theoretical analyses on the capacity to harbor and express
such phenotypic variation have also been reported [23,24].
These theoretical ﬁndings have been corroborated by
experimental data from model organisms [23,24] without
any a priori assumptions regarding the potential genetic
pathways. It is therefore reasonable to extend this approach
to genetic hierarchies and pathways responsible for the
process of aging in humans. We recognize that not all
longevity genes act as buffering mechanisms. Our study
therefore focuses on the discovery of those genes that have a
buffering effect, and their targets, age-related disease genes.
This equivalence suggests that the buffering effect longevity
genes are hypothesized to possess, will allow the accumulation
of deleterious allelic variants in buffered disease genes. In
turn, we expect the prevalence of a deleterious age-related
genotype among centenarians to be maintained at a level
similar to that prior to the onset of the age-related disease
within the (younger) control population. Centenarians,
however, are rare in human populations; thus, an initial
decline in the prevalence of the deleterious genotype in
buffered disease genes is expected. As the population ages,
Figure 1. Genotypic Frequency Comparison between Control and
Proband
Genotypic frequencies of SNPs associated with some of the genes
implicated in CVD. Comparison is between control individuals (;70 years
old), and probands (;100 years old). Offspring of centenarians are
excluded from this analysis. Significant change, p , 0.0066 (after
applying Bonferroni correction), was found for two genes, CETP and
APOC-3. Most genotypes exhibit no change in frequency between the
two groups though they may still be factors contributing to lifespan.
doi:10.1371/journal.pcbi.0030170.g001
Figure 2. Frequency Trend of Two Buffering Genes
Longevity genes are expected to exhibit monotonic increase in their
favorable genotype when sampled in progressively older age groups.
The graph shows a highly significant (p , 0.0006) monotonic increased
frequency across ages for favorable genotypes in APOC-3 CC, and a
significant (p , 0.047) for CETP-VV, fulfilling our definition for candidate
longevity genes.
doi:10.1371/journal.pcbi.0030170.g002
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Buffering Mechanisms in Agingthe proportion of individuals endowed with favorable
genotypes at longevity gene loci increases, as should the
proportion of individuals carrying (the now buffered)
deleterious age-related disease genotype. Thus, such delete-
rious genotypes should exhibit a U-shaped trend with
progressive aging. The following more formal argument
describes this more clearly. We ﬁrst divide the population
(at birth) into those protected by the longevity allele (group
P) and those lacking it. We then further subdivide the latter
group into those with deleterious allele in age-related disease
gene (unprotected group U) and those with wild-type allele
(group N). Since they are unprotected from the deleterious
genes they are carrying, group U is expected to have the
shortest mean lifespan, dU, of the three groups (P, U, and N).
Assuming that the favorable genotype group P has the longest
mean lifespan, dP,( dP . dN . dU), in part because the
longevity allele confers a buffering effect against the
deleterious alleles they may have, then we will observe a U-
shaped curve, which is a consequence of the ﬁnal population
being dominated by group P (see Text S1 and Figure S3 for
simulation results).
Figure 3 shows such a trend for the deleterious variant of
two age-related disease genes, KLOTHO and LPA (see also
Figures S1–S3).
Gene–Gene Interactions To Identify Targets for Longevity
Genes
An important ﬁnal step in our analysis is required—that is,
to associate longevity genes with their potential targets—
buffered disease genes. In the absence of favorable genotypes
in longevity genes, the protective effect, and with it the
accumulation of deleterious genotype in buffered disease
genes, will not occur. Therefore, in a subpopulation lacking
longevity-favorable genotypes, a monotonic decline in the
prevalence of a deleterious genotype in a buffered disease
gene is expected. In contrast, in a subpopulation possessing
the favorable genotype, no change, or an increase, in the
prevalence of deleterious buffered disease genes will be
observed. Figure 4 shows such an interaction between the
deleterious variant of LPA and the two variants of CETP (for
further details see also Figure S2). A limiting factor in this
ﬁnal step is that, since centenarians are rare, we expect the
favorable genotype in longevity buffering genes also to be rare
among younger populations. To overcome this limitation, we
make novel use of the centenarian offspring data. Inheritance
assures that the genotypes among offspring will be enriched
with favorable longevity genotypes. Thus, by admixing the
offspring with a control population, we artiﬁcially enrich the
prevalence of rare longevity genotypes. Because we only make
use of the offspring population in this ﬁnal step, the
identiﬁcation of potential longevity genes and buffered
disease genes (and the analysis of their interactions) is not
affected by the introduction of this artiﬁcial enrichment.
Results
Patterns of Genotypes with Aging
We present the analysis of the 66 common allelic site
polymorphisms in 36 candidate genes for a lipoprotein
phenotype we have studied (see Methods for the population
Figure 3. Observed U-Shape Trend of Age-Related Buffered Disease
Genes
Longevity genes are hypothesized to buffer the phenotypic effect of
certain deleterious age-related disease genotypes, thus allowing the
accumulation of the latter in a population endowed with longevity
genotypes. Presented here are the frequency trends across ages of
deleterious genotypes in KLOTHO and LPA. Frequencies decline until the
population age is ;80 years old, close to the current average lifespan,
and then increases to nearly the frequency in younger age, fulfilling our
definition of a buffered disease gene. We used a binomial model with
identity link function with both linear and quadratic terms for age, and
tested for the significance of the quadratic component. We found a
statistically significant quadratic component at the level of p , 0.035 for
both KLOTHO and LPA.
doi:10.1371/journal.pcbi.0030170.g003
Figure 4. Interaction between CETP and the Buffered LPA Gene
An interaction between the longevity gene and its target buffered
disease gene is revealed by population subdivision. A subpopulation
endowed with the favorable longevity genotype will show either no
change, or an increase, in the frequency of its target deleterious
genotype. In a population lacking the favorable longevity genotype, a
monotonic decline (similar to the decline in nonbuffered disease gene)
will be observed. Presented here are the frequency trends across ages of
deleterious genotype in LPA in the subpopulation having favorable
longevity genotype CETP-VV versus the subpopulation lacking it, i.e.,
CETP-IV and CETP-II. The two trends show a significant difference (p ,
0.037, see Text S1 for statistical considerations).
doi:10.1371/journal.pcbi.0030170.g004
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Buffering Mechanisms in Agingand statistical considerations). Figure 1 visually represents the
frequencies of their genotypes in ;70 and ;100-year-old
subjects (see Table S1 and Text S1 for a complete list). Only
the frequencies of homozygosity for the codon 405 valine (V)
allele of CETP (VV genotype) and the homozygote CC
genotype in the APOC-3 promoter region APOC-3
C(-641)A, have been determined as having a signiﬁcantly
greater prevalence among centenarians (both p-values from
chi-square tests are less than 0.0001, and show statistical
signiﬁcance even after Bonferroni correction). Both geno-
types have been previously associated with increased lip-
oprotein particle size, and thus are associated with a reduced
risk for CVD. For that reason, we considered them favorable
candidates for longevity genotypes [11,25].
The observed greater prevalence of these genotypes in
centenarians compared with the control group as a whole
does not, however, completely satisfy our ﬁrst hypothesis.
That is, for CETP-VV and APOC-3 CC to be considered
favorable longevity genotypes, a monotonic increase with age is
expected. Indeed, this turns out to be the case. Figure 2 shows
a highly signiﬁcant (p , 0.0006) monotonically increasing
frequency trend for APOC-3 CC. For CETP, the monotonic
increase trend is also found to be statistically signiﬁcant (p ,
0.047), making both APOC-3 CC and CETP longevity gene
candidates. The statistical signiﬁcance for a monotonic
increase of favorable genotypes with age was tested using
logistic regression (see Text S1 for details).
Most of the genes we have studied, however, have not been
reported to differ signiﬁcantly in frequency between control
subjects and centenarians—e.g., lipoprotein lipase (LPL),
lymphotoxin alpha (LTA), low-density lipoprotein receptor (LDLR),
and others (see Figure 1). Lack of statistically signiﬁcant
differences, however, do not signify the irrelevance of these
genes to the aging process, since the frequency analysis of the
intermediate age groups may well reveal a more complex
pattern, as will be shown below.
Identifying Buffered Age-Related Disease Genes
To identify buffered disease genes further, a more detailed
examination is required. A deleterious genotype at an age-
related buffered disease gene is predicted to decline initially
as the population ages. As the population approaches
extreme longevity, the initial decline should reverse, and
the prevalence of the deleterious genotype should increase.
Indeed, studies in French and Italian centenarian subjects
[26–28] reported the paradox of an unfavorable genotype and
phenotype that are more common in centenarians. Among
the set of genes tested, we have identiﬁed two such genes: one
is LPA (see Figure 3), which is associated with increased risk
for vascular diseases in the elderly [29]. The other gene shown
in Figure 3 is the age-related disease gene KLOTHO, an aging
gene that is associated with low HDL and reduced CVD risk
[30,31]. The reported frequency trends for both LPA and
KLOTHO follow the expected U-shape trends based on
individuals from the control group only, as described above.
Using statistical assumptions described above (see Methods
and Text S1), we arrived at a statistically signiﬁcant quadratic
component for the genotypic frequency of LPA (p , 0.035). A
similar statistically signiﬁcant result was shown for KLOTHO
(p , 0.035). Interestingly, LPA plasma levels, known to be a
factor for coronary artery disease [32], have also been
measured and found to reﬂect precisely the trends of the
genotype: 15.3 6 1.8 mg/dl in subjects 60–70 years old,
declined to 10.8 6 2.1 mg/dl in subjects aged 71–80 years old,
with an increment to 15.7 6 2.3 mg/dl when subjects achieve
an age of 100 years old.
Longevity Genes and Their Target Age-Related Disease
Genes
To complete our analysis, the buffering effect of longevity
genes on their target age-related disease genes needs to be
determined. As explained above, to ensure the presence of
favorable longevity genes in a younger population, we
supplemented the control population with the offspring of
centenarians. We then divided the pooled, control offspring
population into two subpopulations—those endowed with,
and those not endowed with, a favorable genotype in a
longevity gene, i.e., CETP-VV versus CETP-IV / CETP-II. When
a chi-square test to reveal the interaction between LPA and
CETP genotypes is performed between the 92-year-old age
group (advanced in age, though not yet centenarians) and the
younger 80-year-old group, we ﬁnd a signiﬁcant interaction
with respect to CETP-VV and CETP-IV / CETP-II (p , 0.026,
chi-square). However, the hypothesis described above sug-
gests a stronger result: in a subpopulation endowed with the
favorable CETP genotype (CETP-VV), the frequency trend of
the deleterious genotype of LPA will exhibit no change, or
may even increase, with age. In contrast, a signiﬁcant decline
should be observed in the subpopulation lacking the
favorable longevity CETP genotype. Indeed, such a difference
in frequency trends is observed (see Figure 4). The reported
differences between the observed trends is statistically
signiﬁcant, p , 0.037.
Although we expect to have multiple targets for each of the
longevity genes, not all age-related disease genes may be
targeted by all longevity genes. In case such protection is not
provided, we would not therefore expect to see a signiﬁcant
change in frequency trends between the two subpopulations.
For example, when the same pooled control offspring
population was subdivided on the basis of the favorable
genotype at the APOC-3 locus to test its effect on the
deleterious LPA genotype, no signiﬁcant changes in trend
behavior were observed. In addition, as a test of our
hypothesis, a similar interaction analysis was performed on
the KLOTHO genotype. Since no data from centenarian’s
offspring were available for the gene–gene interaction
analysis, we included individuals from the centenarian
population. When an interaction between CETP and KLO-
THO exists, one would expect the admixed, control-cente-
narians population to exhibit a more signiﬁcant interaction
term than that obtained by an admixed control-offspring
population. However, no signiﬁcant interaction was found
when associating CETP or APOC-3 genotypes individually
with the unfavorable KLOTHO genotype (P ¼ 0.38 and P ¼
0.85, respectively). Figure 5 shows that the KLOTHO’s
frequencies for the two subpopulations, with and without
favorable CETP genotype, follow a similar U-shape trend. The
lack of interaction suggests that, though CETP and KLOTHO
may both have an inﬂuence on lipoprotein size, no buffering
mechanism can be inferred.
Toward Building the Genetic Network of Aging
Finally, to corroborate our ﬁndings with existing knowl-
edge about interactions among the set of genes we have
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Buffering Mechanisms in Agingidentiﬁed, we applied a two-stage network analysis. First,
using GRID (General Repository of Interaction Database), we
identiﬁed all the possible targets of CETP, LPA, and APOC-3
(primary interactions), and then extended the scope to
include secondary and tertiary interactions which resulted
in a network of 248 nodes and 450 edges. From this extended
network, we then selected those genes that lie on the
minimum pathways (shortest path length linking two nodes)
among CETP, LPA, and APOC-3. This resulted in the
following additional genes: APOE, LPAL2, PLTP, and APOA1.
In the second stage, we used the PathwayArchitect software
application (Stratagene, http://www.strategene.com) to fur-
ther corroborate the resulting interaction network. Results of
this analysis yielded a similar outcome, that is, the same genes
resulted in having the highest conﬁdence index of inter-
actions in the pathway layout graph. Figure 6 delineates a
subnetwork of known interactions among proteins relevant
to our hypothesis. As can be observed, CETP indeed interacts
with LPA. This interaction is two-fold, via LPAL2, a LPA-like 2
lipoprotein, and again, through LPAL2 via APOA1 apolipo-
protein A-1 [33,34]. These ﬁndings call for further analysis of
the role of the LPAL2 and APOA1 proteins. Interestingly,
although the pathway analysis revealed direct contact
between APOC-3 and LPA [35–38], the hypothesis test
revealed that buffering does not occur between APOC-3
and LPA, since there exists no signiﬁcant interaction (p ¼
0.076). This observation suggests that given the similar
biological effect APOC-3 and CETP has on lipoprotein size,
buffering is most likely mediated by other, yet to be
discovered, biological means. Finally, when the KLOTHO
protein was introduced into the pathway analysis, no addi-
tional links were found, nor did we ﬁnd any link between
KLOTHO and any of the subset of proteins tested. This
ﬁnding is in accord with our hypothesis, due to lack of
interaction between CETP or APOC-3 and KLOTHO.
Corroborating our hypothesis with known protein interac-
tions indicates that our analysis can predict and be used to
further suggest interactions not yet known.
Discussion
Recent progress in the search for candidate aging genes in
centenarian studies has been signiﬁcantly helped by the
availability of more sensitive statistical techniques [39,40]. For
example, an allele-speciﬁc association with longevity was
found for SOD2 [41] due to the increased sensitivity of the
relative risk method [42,43] over the gene frequency method
[41]. Given the important polygenic aspects of the aging
phenotype, an approach that searches for candidates within
their genetic context is urgently needed. Previous work has
already demonstrated the importance of genetic background
for longevity, suggesting a role for epistasis [44,45]. The study
we present here moves further in this direction by not only
giving the genetic background a central role, but furthermore
suggesting a novel mechanistic explanation based upon
previous theoretical results on gene–gene interactions and
buffering.
A previously unfavorable LPA genotype has been reported
to be paradoxically increased in French and Italian studies of
centenarians [26–28], representing an increased frequency of
disease genotype in centenarians. Our results suggest that a
harmful genotype probably does not turn into a protective
one, but rather indicates a protection by other favorable
longevity genotypes. Indeed we show that increased CETP-VV
genotype, CETP levels, and favorable lipoprotein sizes may
buffer the deleterious effects of LPA genotypes, thus allowing
the accumulation of unfavorable genotypes among centenar-
ians. Similar U-shaped patterns of genotypic frequency with
respect to age have also been reported by Tan et al. [42] for
the C282Y allele and by Cavallone et al. [46] for the PON1
gene, making them candidates for further analysis as buffered
age-related disease genes.
To identify the frequency pattern of genotypes associated
with aging and longevity, any analysis must include repre-
sentation of all age groups. Because the nadirs of frequencies
for LPA and KLOTHO genotypes were at age ;80, previous
studies that identiﬁed putative longevity genotypes (due to
rising life expectancy from ages 80 to 100), may have
identiﬁed protected aging genes but not true longevity genes.
Comparing populations at ;50 and ;100 years old would
potentially exclude individuals possessing aging genes that
may be buffered at a later age. It is also important to realize
that, because we have obtained a large number of rare
individuals with exceptional longevity, classical genetic rules,
such as the Hardy-Weinberg equilibrium, do not apply in this
population. This should be retrospectively considered in
groups of centenarians whose results were dropped because
they violated the Hardy-Weinberg equilibrium. In other
words, because the genotypes of survivors are ‘‘selected,’’
the greater the attribution of a genotype to longevity, the
greater is the divergence from Hardy-Weinberg equilibrium
among the elderly.
The focus of the current study has been on the longevity
genes of centenarians. However, given the complexity of the
trait, which may derive from multiple, redundant pathways,
pleiotropic interactions, and other environmental factors, it
is highly likely that different individuals achieve longevity by
different means. Parallel studies in other isolated popula-
tions, such as the Icelandic, will provide the means to address
new pathways for longevity. Conﬁrming these ﬁndings in the
general population will also facilitate identiﬁcation of
Figure 5. Interaction between CETP and the Buffered KLOTHO gene
Comparable to Figure 4, we show here the frequency trends across ages
of deleterious genotype in KLOTHO in the subpopulation having
favorable longevity genotype CETP-VV versus subpopulation lacking it,
i.e., CETP-IV and CETP-II. Because of the lack of offspring data, we
included centenarians (see text). The two frequency trends follow a
similar U-shape with age and show no significant interaction term (p ,
0.38). Nonsignificant results have also been observed for the interaction
term between APOC-3 and KLOTHO (unpublished data).
doi:10.1371/journal.pcbi.0030170.g005
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longevity involves a far more complex relationship among
longevity and disease genes than the pairwise interactions we
have introduced here. Yet, our results suggest that this
approach can contribute to our understanding of processes
as complex as aging. We used two examples of genotypes that
seemed to protect from several age-related conditions. Thus,
we expect each of these genotypes to provide protection
against several aging genotypes. Indeed, we conclude that
investigating the genetic pathways for ‘‘aging phenotypes,’’
such as age-related disease and the pathways that buffer these
effects, combined with analyses of quantitative traits, may
suggest strategies to modulate the disease phenotypes of
aging. For example, if any single longevity gene buffers
against several aging genes, agents could be developed to
exploit such a drug with widespread protective effects.
Methods
Population and genotypes studied. Our population, Ashkenazi
Jews, is an ideal study group because social, political, and religious
pressures limited this population to a relatively few founders [47].
This genetic homogeneity is paralleled by a relatively homogeneous
socioeconomic and educational status. Inbreeding in this population
has allowed successful genetic research in Ashkenazi Jews, including
the characterization of multiple rare autosomal recessive disorders
such as Tay-Sachs disease [48], factor XI deﬁciency [49], and
hyperinsulinemic hypoglycemia of infancy (i.e., sulfonylurea receptor
mutations) [50], as well as common diseases such as breast and
ovarian cancer (i.e., BRCA1 and BRCA2 gene mutations) [8]. A
limitation of this model is the lack of inclusion of a complex gene-
environment interaction. However, by selecting an environmentally
homogeneous population, we minimize the effects of such inter-
action.
Three hundred and ﬁve probands with exceptional longevity (228
females and 77 males, age 98.2 (0.36) years [mean (SE)], range 95–109
years; 48% over the age of 100 years) were recruited to participate in
the study. Birth certiﬁcates or dates of birth as stated on passports
deﬁned the participants’ ages. Probands were required to have been
living independently at 95 years of age as a reﬂection of good health,
although at the time of recruitment they could be at any level of
dependency. In addition, for inclusion probands were required to
have a child who was willing to participate in the study. The offspring
group consisted of 227 females and 203 males (age 68.3 [0.45] years,
range 54–89 years). Finally, the control group consisted of 265
females and 203 males (age 69.5 [0.52] years, range 54–90 years),
matched in age to the offspring. Details regarding the recruitment
and demographics of this group can be found in [11,16,17] (see Table
1 for age distribution of the subjects recruited).
To test our hypothesis, we determined the prevalence of 66
common polymorphic sites in 36 genes that are known to be risk
factors for cardiovascular disease (CVD) using a multilocus PCR-
based genotyping assay. Brieﬂy, DNA was ampliﬁed using multiplex
reaction containing biotinylated primer pairs. Ampliﬁed fragments
within each PCR product pool were then detected colorimetrically
with sequence-speciﬁc oligonucleotide probes immobilized in a
linear array on nylon membrane strips. Probe speciﬁcities had
previously been conﬁrmed by sequencing and by use of DNA
genotyped independently through other methods such as restriction
length polymorphism analysis [51].
Statistical considerations. The following are the statistical consid-
erations in identifying potential buffered disease genes contributing
to the aging phenotype. Among the SNPs which demonstrate a
signiﬁcant decline in frequency with age in the control group, we
examined those in which the prevalence is signiﬁcantly higher in the
centenarian population relative to the control 80–90 age group. The
identiﬁed SNPs are those associated with candidate-buffered disease
genes. For those SNPs which show an initial signiﬁcant decline with
age followed by a signiﬁcant increase, that is, a U-shape trend of age-
Figure 6. Protein–Protein Interaction Network
Protein–Protein interaction networks of subsets of proteins relevant to the buffering hypothesis analysis. Connecting lines between gene symbols
indicate interactions; different types of interactions are denoted by symbols on the lines. Green square, regulation; blue square, expression; light green
triangle, transport; þ in grey circle, positive effect;   in grey circle, negative effect. CETP interacts with LPA through LPAL2, an LPA-like 2 protein. This
interaction is also mediated by LPAL2 through APOA1, and apolipoprotein A-I. Also, though our analysis shows no interaction between LPA and APOC-3,
pathway analysis shows a direct interaction, suggesting additional and non-overlapping functionality between CETP and APOC-3 (see text).
doi:10.1371/journal.pcbi.0030170.g006
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linear model with data from the combined control and centenarian
groups. We use a binomial model with an identity link function and
both linear and quadratic terms for age, and test for the signiﬁcant
quadratic component. More speciﬁcally, the binary response (Y) of
having (Y ¼ 1) or not having (Y ¼ 0) the deleterious genotype of an
age-related disease gene is modeled as P(Y ¼ 1) ¼ b0 þ b1age þ b2age
2.
Note that the standard logistic regression does not apply to this case
since it models probability as monotonic to covariates. Maximum
likelihood estimates of the coefﬁcients b0,b 1,b 2 are obtained by the
Fisher Scoring method. The statistical signiﬁcance of the quadratic
term is then determined by the likelihood ratio test that compares
the likelihood of the model of b2 6¼ 0 with the model of b2 ¼0. If the
quadratic term is signiﬁcant and the minimum of the quadratic
function  b1/(2b2) falls within age range of our subjects, the relevant
gene is further considered. To formally test the statistical signiﬁcance
of the interaction term between frequency trends of the two
subpopulations (those endowed with and without favorable genotypes
at the longevity gene), it is equivalent to test the statistical
signiﬁcance of interaction effects between the factor ‘‘age’’ and the
‘‘longevity genotype’’ factor, using logistic regression. The binary
response in the logistic regression is whether or not a subject has the
deleterious genotype of the buffered disease gene. To test the
signiﬁcance of age–gene interaction, the model with main effect only
and the model with the interaction effects are compared using log-
likelihood ratio test (for additional information see Text S1).
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Line-a, longevity genes. Line-b, age-related diseases genes. Line-c,
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